FDG-PET – Medxy AI

Unveiling Metabolic Signatures: Glucose and Methionine PET Imaging in Disorders of Consciousness Post-Brain Injury

By MedXY 08/26/2026

This exploratory longitudinal study reveals that alongside decreased glucose metabolism, elevated brainstem methionine uptake correlates with consciousness improvement in brain-injured patients, highlighting novel metabolic biomarkers for prognosis in disorders of consciousness.

news Oncology Radiology

Early FDG-PET Predicts Survival Outcomes in Metastatic Breast Cancer: IMPACT-MBC Trial Reveals Rapid Response Imaging as a Powerful Prognostic Tool

By MedXY 04/18/2026

The IMPACT-MBC trial demonstrates that performing FDG-PET after just 2 weeks of first-line systemic therapy can accurately identify metastatic breast cancer patients with distinct long-term outcomes, potentially improving treatment decision-making and patient counseling.

news Oncology Otorhinolaryngology

FDG-PET-Guided Dose De-escalation: A New Standard for HPV-Positive Oropharyngeal Cancer?

By MedXY 01/11/2026

A multi-center phase II trial demonstrates that mid-treatment FDG-PET imaging can safely identify patients with HPV+ oropharyngeal cancer for radiation dose reduction, resulting in non-inferior tumor control and significantly improved quality of life.